9/15/2022 12:00:00 AM

Gene Lay Awarded the Medal of Honor of the German Society for Immunology

BioLegend President and CEO Gene Lay was awarded the Medal of Honor by the German Society for Immunology (DGfI) in recognition of his great commitment to basic research and his everlasting support of numerous immunological societies.


Read the announcement>>

4/8/2022 12:00:00 AM

BioLegend Wins 2022 CiteAb Award

The CiteAb Awards celebrate the very best suppliers and individuals in the research reagent sector worldwide. BioLegend is recognized as a Multiplex Immunoassay Supplier to Watch in 2022. This exciting new award recognizes the supplier growing in the multiplex immunoassay field, set to make big moves in the market.


Read the announcement >>

1/1/2022 12:00:00 AM

BioLegend Announces Acquisition of Qognit

January 1, 2022: BioLegend is excited to announce the acquisition of Qognit, a cloud-based software company focused on the challenges of single-cell data: high-dimensionality and large scale. The addition of Qognit complements the BioLegend portfolio of high-quality reagents with software solutions that enable customers to analyze their results and drive legendary research and discovery.


The acquisition includes the extensive knowledge base and expertise of the Qognit team in developing solutions for the life sciences market, from multiplex assays to multiomics analysis. Qognit and BioLegend both look forward to continuing to make a difference in the scientific community with our world-class quality solutions, superior customer support, and outstanding value.

9/17/2021 12:00:00 AM

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 17, 2021-- PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.

The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.

Read press release >>

7/30/2021 3:00:00 PM

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

PerkinElmer, Inc. announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.

Gene Lay, founder, president and chief executive officer of BioLegend, “We are very excited to join the PerkinElmer family. The combination will afford us the opportunity to continue to build on our two-decade foundation of innovative science and scale in new and highly attractive PerkinElmer areas such as clinical diagnostics and food safety testing. The BioLegend team is eager to enter this new chapter with PerkinElmer, furthering our mission of enabling legendary discovery from research to cure.”


Read press release >>


12/3/2020 3:00:00 PM

TotalSeq™-C Universal Cocktail Wins A Top Innovation of 2020 Award

The ScientistBioLegend is excited to announce that our TotalSeq™-C Human Universal Cocktail v1.0 was named one of The Scientist’s Top 10 Innovations of 2020. Every year, The Scientist recognizes the year’s most innovative products that make work more efficient and facilitate biological discovery.

Our TotalSeq-C Human Universal Cocktail contains pre-optimized, oligo-conjugated antibodies and associated controls to simultaneously detect 130 targets using single-cell sequencing. The cocktail is compatible with 10x Genomics’ Single-Cell Immune Profiling Solution, providing an unprecedented view of immune cells by combining single-cell surface protein detection, transcript sequencing, and full-length paired B cell and T cell receptor sequencing. Discover how this technology can help your research by visiting our comprehensive TotalSeq webpage.


9/2/2020 12:00:00 AM

MDSAP Initial Certificate

BioLegend, headquartered in San Diego, CA, has passed the Medical Device Single Audit Program (MDSAP) certification audit in October, 2019. BioLegend’s Quality Management System was audited by notified body; TÜV SÜD, an accredited certification body for ISO 13485:2016 and MDSAP, and was found to conform to the requirements for MDSAP, as well as ISO 13485:2016. The certification is part of BioLegend’s commitment to quality, continuous improvement, and enabling legendary discovery from research to cure, allowing the company to move forward with diagnostic products and GMP grade proteins globally.

3/23/2020 12:00:00 AM

UPDATE: A Message from BioLegend's CEO


In addition to several other states, California is now under a “shelter in place” order. This order requires residents to stay in their homes except for certain essential activities. In addition, many state governments are ordering non-essential businesses to close temporarily. Certain workers and businesses that provide services deemed as critical to the healthcare system, food supply, and energy supply are exempted from this order. 

BioLegend is headquartered in San Diego, California. However, given the critical role we are playing in helping our customers research cures for SARS-CoV-2, BioLegend is designated as an essential business. We are continuing to operate normally without production or distribution disruptions while taking the utmost precautions to protect our employees and customers.

If you are closing operations or changing procedures for receiving orders, need assistance in contingency planning, or have any other questions, please contact your local FAS or distributor or contact Customer Service via email at cs@biolegend.com, or by phone at 1-877-Bio-Legend (1-877-246-5343). We have also posted an FAQ with additional details.

We continue to closely monitor this dynamic situation to ensure we are taking all the steps necessary to keep our customers operational so they can continue their life-saving research. 

Please stay safe and healthy.

Gene Lay, CEO, BioLegend


3/13/2020 12:00:00 AM

A Message from BioLegend’s CEO Regarding the Coronavirus (COVID-19)


Dear Valued Customer,


In light of the dynamic circumstances around the Coronavirus (COVID-19), BioLegend would like to reassure you that we are constantly monitoring the situation with the goal of maintaining uninterrupted shipments of our products, while also protecting the health of our employees around the world.


Currently, the manufacturing and distribution of our products is business as usual. BioLegend manufactures all of our products, and sources a vast majority of our components, in the USA. Our three distribution centers in San Diego, the United Kingdom, and the Netherlands, are maintaining normal business operations. At this time, we have no significant concerns related to our supply chain, distribution, or on-time delivery to our customers.


While we are continuing to operate regularly, we recognize that it may not be business as usual for you. As your trusted partner, we are here to help you in mitigating potential disruptions in your research. For our customers in countries served by our distributors, we are closely coordinating with our partners to ensure their inventories and delivery operations are fully supported.


For additional information, please reach out to your local FAS or Distributor or call Customer Service at 1-877-Bio-Legend (1-877-246-5343) or email infoeurope@biolegend.com to assist in contingency planning. We have also posted an FAQ that provides additional details on our strategy to support you and your teams during this challenging time.




Gene Lay, CEO, BioLegend


COVID-19 Statement



Frequently Asked Questions


Q1. Are there any anticipated disruptions to BioLegend’s delivery of its products?
No. At this time, we are operating normally and do not expect disruptions in shipping our products. We are constantly monitoring the situation with the goal of continuing to work with our customers to deliver products while ensuring the safety of our employees.


Q2. Where are BioLegend’s products manufactured?
All BioLegend products are manufactured in the United States, and we do not anticipate disruption of manufacturing at this time.


Q3. Where does BioLegend obtain the components used to make BioLegend products?
A vast majority of the components used to make BioLegend products are sourced in the USA, and we do not anticipate supply issues at this time.


Q4. Who should I contact if I anticipate any disruption to my business such as the ability to receive shipments, ordering, etc.?
Please contact your local FAS or Distributor if you anticipate any issues. We will work with you to provide support and ensure the best customer solution possible.


Q5. Where are BioLegend’s distribution centers?
BioLegend has three warehouses: USA-San Diego, CA, Netherlands-Amsterdam, and United Kingdom-London. All distribution centers are conducting normal business operations. As an extra precaution, many of our distribution partners around the world will also hold stock at levels advised by BioLegend.


Q6. What is BioLegend’s contingency plan for fulfilling orders?
BioLegend has three warehouses: USA-San Diego, CA, Netherlands-Amsterdam, and United Kingdom-London. Each site will serve designated regions. In case of an emergency, Customer Service in San Diego, CA (CS@biolegend.com) or email infoeurope@biolegend.com will take all orders and coordinate shipping.

We continue to assess this dynamic situation worldwide, and we are prepared to entertain various staffing options, combined with cyclic decontamination, to minimize any product delivery disruptions. Throughout, we will always prioritize the safety of our employees. For BioLegend customers not directly served by the listed warehouses, many of our distribution partners around the world also hold stock at levels advised by BioLegend.

If you need additional assurances of product availability, please contact your local FAS or Distributor so we can work together to continue normal business operations.


Q7. Are there specific disruptions or new protocols in China?
Dakewe, our distributor in China, has resumed business as of late February. We will continue to provide products to customers in China through this partnership as long as operations in the USA remain undisrupted.


Q8. Are there specific disruptions or new protocols in Europe?
Both our United Kingdom and Netherlands facilities are operating as normal. In the event that either or both facilities become inoperable, our flagship operation in San Diego, CA, USA is fully capable of stepping in to support all European customer requirements.


Q9. Are there specific disruptions or new protocols in North America?
Fulfilling customer orders is our first priority in any situation. The San Diego warehouse is operating as normal, and we are prepared to focus on order fulfillment under any reduced resource scenarios. Please contact Customer Service (CS@biolegend.com) or your FAS for any concerns regarding your orders.


Q10. How do I notify BioLegend if we will not be able to receive pending orders?
For information or questions regarding orders, please reach out to your local FAS or Distributor or call Customer Service at 1-877-Bio-Legend (1-877-246-5343) or email infoeurope@biolegend.com to discuss potential delivery options.


Q11. Can I receive my inventory currently stocked at BioLegend sooner than scheduled?
Please contact your local FAS or Distributor for available stock and shipping options.


Q12. Should I stock up on my orders now in case of a future emergency?
Given the dynamic nature of the situation, we cannot advise whether you should stock up. Please contact your local BioLegend FAS to discuss best options.

5/9/2019 12:00:00 AM

BioLegend Moves Global Headquarters to Newly Constructed, State-of-the-Art Campus in San Diego, California

BioLegend Campus Inauguration Symposium focused on Cancer Immunotherapy features Nobel Laureate and World-Renowned Immunologists 

(San Diego, CA – May 9, 2019) BioLegend, leading provider of world-class biological reagents and tools that enable life science discovery from research to cure, today announced the opening of its new global headquarters located at 8999 BioLegend Way in San Diego, California. The expansive 8-acre campus is designed to support the company’s growth, provide an attractive environment for new talent, and better serve customers worldwide.

To celebrate the grand opening of its new headquarters, BioLegend hosted an inaugural symposium focused on Cancer Immunotherapy on Wednesday, May 8 which brought a crowd of 300 top scientists, business leaders, and trusted partners. The symposium was hosted by Dr. Gene Lay, Founder and CEO of BioLegend. The scientific program included talks by five world-renowned immunologists, including 2018 Nobel Laureate, Professor James P. Allison, PhD.

The official ribbon cutting ceremony was attended by key dignitaries including the Mayor of San Diego, Kevin Faulconer. BioLegend received a Proclamation and a Commendation, presented by representatives from California’s 52nd Congressional District and San Diego City Council, respectively.

“The innovation economy continues to thrive in San Diego thanks to our highly talented workforce and companies like BioLegend that are helping make groundbreaking discoveries right here in our backyard,” said Mayor Kevin L. Faulconer. “BioLegend’s decision to build their campus here is a strong affirmation of San Diego’s role as a biotech hotbed. We look forward to BioLegend paving the way for more scientific discovery, creating more good-paying jobs for San Diegans, and building a brighter future for people across the globe.”

For BioLegend employees and visitors, the new campus offers amenities that integrate beauty and function. The facilities were built with a focus on sustainable business practices, including a green roof, solar panels, and electric charging stations in the parking structure. The goal of the new campus is to enable collaboration between departments while providing efficient laboratories and workspaces where employees can thrive. A technological highlight is San Diego’s first-ever installation of a robotic picking system, which is the first worldwide in a cold storage space. These features will help BioLegend fulfill orders at a faster pace with improved accuracy.

“BioLegend is proud to be enabling discoveries that improve human health, in cancer therapy, neuroscience, and immunology. Our new state-of-the-art campus allows us to expand the breadth and depth of our research and diagnostics portfolios to accelerate cures for debilitating diseases,” said Gene Lay, CEO of BioLegend. “The campus was built to accommodate more than 1,000 employees and we look forward to creating new job opportunities for San Diego residents and growing our scientific talent base to meet our customers’ needs.”

For more information about BioLegend, please check out our website www.biolegend.com.

Media Contact:

Maria Thompson

Dzung Nguyen, Director, Marketing


About BioLegend

BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we have secured loyal customers and trusted partners at the world’s premier research institutions, biotechnology and pharmaceutical companies. Our scientists collaboratively develop cutting-edge research and diagnostic products, establishing BioLegend as a global leader in immunology, cancer research, neuroscience, cell biology, proteogenomics, stem cells, and other emerging sectors. Recognized as one of the fastest growing life science companies, BioLegend transforms the boundaries of innovation for basic science and medical researchers worldwide. To learn more, visit www.biolegend.com.

BioLegend President & CEO Gene Lay, Mayor Kevin Faulconer, Symposium Speakers, San Diego City Dignitaries, and
BioLegend Senior Executive team. (Photo: BioLegend)

3/21/2019 12:00:00 AM

BioLegend commended in 2019 CiteAb Awards

BioLegend was highly commended in the 2019 CiteAb Awards in two categories as a Rising Star in Immunology and as an Antibody Company Succeeding in Japan. Learn more about CiteAb and their goals by visiting their webpage.

11/14/2018 12:00:00 AM

BioLegend partners on TotalSeq™ antibodies to boost single cell surface protein profiling within VIB



BioLegend, a world-class antibody provider, announced today a new partnership with VIB, a leading life science research institute in Flanders (Belgium), to evaluate and implement the TotalSeqTM antibodies for next-generation multi-omics by the combining single cell transcriptomics with single cell proteomics profiling.

Early this year, an exclusive license agreement was announced between BioLegend and the New York Genome Center to commercialize CITE-seq under BioLegend’s brand name TotalSeqTM. The first product in the brand portfolio, TotalSeqTMA, was the first to provide a commercially available source for CITE-seq antibodies to enable simultaneous surface protein profiling and RNA-seq at the single cell level. BioLegend’s more recent collaboration with 10x Genomics further extends the TotalSeqTM portfolio with TotalSeqTMB and TotalSeqTMC products, which provide more complete reagent kits that are fully compatible with 10x Genomics' ChromiumTM Solutions and new Feature Barcoding technology, recently launched at the ASHG 68th Annual Meeting in San Diego. 

Today, BioLegend and VIB are proud to announce their collaboration on the TotalSeqTM antibody libraries. “BioLegend is thrilled to be working with VIB to provide our integrated TotalSeqTM Proteogenomics solutions as a standardized tool for researchers across labs and disciplines throughout the VIB network,” stated Gene Lay, CEO at BioLegend.

The VIB research institute is at the forefront of the single cell field characterizing pathologies at the highest resolution. Multiple VIB groups will highly benefit from this extremely powerful technology. Martin Guilliams and Charlotte Scott, VIB-UGent Center for Inflammation Research comment that, “One of the main rate-limiting steps of our research, was screening for surface proteins. BioLegend proposes a TotalSeqTM solution that permits to test the expression of hundreds of surface proteins simultaneously in parallel with single-cell RNA-Sequencing. These TotalSeqTM antibodies will now be used in our efforts to map the different myeloid cells for the Human Cell Atlas project.” The TotalSeqTM antibodies will also have a significant impact in the cancer field, states Diether Lambrechts, director of the VIB-KU Leuven Center for Cancer Biology who “plans to apply CITE-seq to examine individual tumor cells and the cells that infiltrate the tumor such as T-cells and other immune cells in tumor biopsies, to deeply characterize tumors and their microenvironment for the development of new immunotherapeutic approaches.” Jo Van Ginderachter, VIB Center for Inflammation Research at VUB, adds that in the brain research field “TotalSeqTM antibodies will generate unprecedented insight in the molecular make-up of single cells present within the steady-state and diseased brain, allowing the identification and characterization of functionally important cell types and activation states.” Bart Lambrecht, director of VIB-UGent Center for Inflammation Research, is “very excited to be able to push the boundaries of flow cytometry panel design to tackle fundamental problems in asthma in an unbiased manner using TotalSeqTM antibodies.” Finally, Yvan Saeys and Niels Vandamme, VIB-UGent Center for Inflammation Research, add to this that "The new TotalSeqTM antibodies provide also novel opportunities for research in computational biology, paving the way towards single-cell multi-omics data integration."

Boosting the VIB research in the single cell field is also one of the key goals of the newly established Single Cell Accelerator (SCA) program at the institute. This program aims to expand VIB’s expertise in single cell research by optimizing, validating and developing novel and recently commercialized platforms within VIB’s Technology Innovation Lab. Over the coming months, VIB will work towards setting up established CITE-seq protocols for this technology on a broad range of different sample types. “We believe that single cell protein profiling can revolutionize the single cell field and we want to boost the uptake of this technology at VIB. For this, we are pleased to be closely collaborating with BioLegend on their TotalSeqTM antibody libraries”, states Silvie Van den Hoecke, Life Science Technology Specialist at VIB.

About VIB
VIB is a research institute based in Flanders, Belgium. With more than 1470 scientists from over 60 countries, the institute performs basic research into the molecular foundations of life. Through the close partnership between VIB and five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University, 75 research groups unite in a single institute to push the boundaries of life sciences. The embedded Tech Watch program supports VIB scientist by actively implementing novel technologies throughout the institute. Over the years, Tech Watch has gathered in-depth information about disruptive technologies that drives the institute. Tech Watch recently established the Technology Innovation lab for rapid implementation of emerging platforms and the development of new technology platforms.

About BioLegend
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, neuroscience and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services, including assay development, sample testing, and conjugation. BioLegend headquarters in San Diego, CA operates under an ISO 13485:2003 certified quality management system. For more information on BioLegend, visit: https://www.biolegend.com/en-us/totalseq

8/30/2018 12:00:00 AM

August 2018 Travel Award Winner Announced

August Travel Award Winner Announced

Congratulations to James Pearson, from Yale University School of Medicine, the August winner of BioLegend's Monthly Travel Award.

To find out more information and to enter to be this month's winner, Click Here.

  • Page 1 of 1

Remember me
Forgot your password? Reset Password
Request an Account